OnKure Therapeutics, Inc. (OKUR) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 12K | 0 | 0 | 0 | 43K | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | -12K | 0 | 0 | 0 | -43K | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | 100% | - | - | - | 72.09% | - | - | - | - | - |
| Operating Expenses | 15.62M | 14.13M | 15.5M | 16.32M | 17M | 33.8M | 4.66M | 14.34M | 9.83M | -21.11M | 20.65M | 8.63M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 3.91M | 3.4M | 3.59M | 3.71M | 3.99M | -3.56M | 3.77M | 3.59M | 1.26M | -14.22M | 7.07M | 1.12M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 11.71M | 10.72M | 11.91M | 12.61M | 13.01M | 37.36M | 892K | 10.75M | 8.57M | -6.89M | 13.58M | 7.51M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -15.62M | -14.13M | -15.5M | -16.32M | -17M | -33.8M | -4.67M | -14.34M | -9.83M | 21.11M | -20.7M | -8.63M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 8.15% | 58.2% | -231.79% | -13.81% | -72.92% | -260.07% | 77.42% | -66.12% | - | - | - | - |
| EBITDA | -15.62M | -13.92M | -15.3M | -16.11M | -16.79M | -33.17M | -4.66M | -14.2M | -9.68M | 21.55M | -20.65M | -8.48M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 6.99% | 58.03% | -228.26% | -13.5% | -73.43% | -253.96% | 77.44% | -67.41% | - | - | - | - |
| D&A (Non-Cash Add-back) | 0 | 202K | 204K | 212K | 212K | 622K | 12K | 148K | 151K | 434K | 43K | 155K |
| EBIT | 0 | -13.5M | -14.7M | -15.39M | -17M | -31.78M | -3.69M | -14.11M | -9.83M | 21.11M | -19.2M | -8.18M |
| Net Interest Income | 0 | 622K | 802K | 934K | 1.07M | 0 | 0 | 204K | 295K | 0 | 0 | 451K |
| Interest Income | 458K | 628K | 804K | 934K | 1.07M | 0 | 0 | 230K | 295K | 0 | 0 | 451K |
| Interest Expense | 0 | 6K | 2K | 0 | 0 | 0 | 0 | 26K | 0 | 0 | 0 | 0 |
| Other Income/Expense | 0 | 622K | 802K | 934K | 1.07M | -1.4M | 980K | 204K | 295K | -2.59M | 1.5M | 451K |
| Pretax Income | 0 | -13.5M | -14.7M | -15.39M | -15.93M | -35.19M | -3.69M | -14.14M | -9.54M | 18.52M | -19.2M | -8.18M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | - | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | 0 | -13.5M | -14.7M | -15.39M | -15.93M | -35.19M | -3.69M | -14.14M | -9.54M | 18.52M | -19.2M | -8.18M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 100% | 61.63% | -298.13% | -8.85% | -67% | -290% | 80.77% | -72.78% | - | - | - | - |
| Net Income (Continuing) | 0 | -13.5M | -14.7M | -15.39M | -15.93M | -35.19M | -3.69M | -14.14M | -9.54M | 18.52M | -19.2M | -8.18M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.11 | -0.99 | -1.09 | -1.14 | -1.19 | -2.64 | -0.28 | -1.06 | -0.71 | 1.39 | -1.44 | -0.61 |
| EPS Growth % | 6.72% | 62.5% | -289.29% | -7.55% | -67.61% | -289.93% | 80.56% | -73.77% | - | - | - | - |
| EPS (Basic) | -1.11 | -0.99 | -1.09 | -1.14 | -1.19 | -2.64 | -0.28 | -1.06 | -0.71 | 1.39 | -1.44 | -0.61 |
| Diluted Shares Outstanding | 13.67M | 13.52M | 13.51M | 13.51M | 13.42M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M |
| Basic Shares Outstanding | 13.67M | 13.52M | 13.51M | 13.51M | 13.42M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M | 13.34M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |